UNSPSC 51152063: Nelezaprine maleate

This classification denotes a muscle relaxant with the molecular formula C18H21ClN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Q9L107XJB, chemically known as 3-(9-chloro-5,6-dihydro-11-h-pyrrolo(2,1-b))(3)benzazepine-11-ylidine-n,n-dimethyl-1-propanaminebutenedioate but more generally known as nelezaprine maleate, which bears US NIH Compound Identifier 6436129. Most nations, for tariff and trade purposes, schedule nelezaprine maleate under HS 29339930 and SITC 51577.

As of Q4 2014, NELEZAPRINE MALEATE remains US FDA's Preferred Term for this commodity. Nelezaprine maleate bears US NLM identifiers UMLS ID C2825399 and NCI Concept Code C80980. SMILES: CN(C)CC/C=C\1/C2CCCN2CCC3C1CC(CC3)CL.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51152063 Nelezaprine maleate is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local procurement activity shows minimal engagement with this exact material. The single recent opportunity in the dataset—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026—solicits naloxone and safe drug deactivation systems, which are distinct product categories from nelezaprine maleate. The county is purchasing 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford. While the opportunity addresses pharmaceutical harm-reduction products aligned with public health and community safety, the specific commodity code appears to misalign with the work actually being bought. Issuing bodies under this code show limited recent activity; Seminole County represents the only documented state or local procurement in the recent-opportunities block.

Geographic activity centers on Florida, specifically Seminole County, with no additional jurisdictions visible in the recent solicitations. The Seminole County IFB carries a response deadline of July 26, 2023—a past date that reflects posting delays or data-entry issues in the source. Vendors bidding under this opportunity must comply with drug-free workplace certification, E-Verify requirements, and insurance provisions including workers' compensation and commercial general liability, with quarterly delivery obligations and a two-year initial term plus one-year renewal option. Potential FEMA funding introduces federal compliance requirements such as the Clean Air Act and Federal Water Pollution Control Act. The code shows little recent relevant activity, suggesting either low state and local demand for this particular pharmaceutical compound or consistent miscoding of naloxone and drug-deactivation product procurements at the commodity level.